<SEC-DOCUMENT>0001095981-14-000027.txt : 20140805
<SEC-HEADER>0001095981-14-000027.hdr.sgml : 20140805
<ACCEPTANCE-DATETIME>20140805160643
ACCESSION NUMBER:		0001095981-14-000027
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140805
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140805
DATE AS OF CHANGE:		20140805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYTORI THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001095981
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330827593
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34375
		FILM NUMBER:		141016216

	BUSINESS ADDRESS:	
		STREET 1:		3020 CALLAN ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584580900

	MAIL ADDRESS:	
		STREET 1:		3020 CALLAN ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MACROPORE INC
		DATE OF NAME CHANGE:	20010320
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cytori_8k080514.htm
<DESCRIPTION>CYTORI THERAPEUTICS FORM 8-K
<TEXT>
<html>
<head>
    <title>cytori_8k080514.htm</title>
    <!--Licensed to: Cytori Therapeutics, Inc.-->
    <!--Document Created using EDGARizer 2020 5.4.6.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">Form 8-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Current Report</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date of Report<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>(Date of earliest event reported):<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160; August 5, 2014</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 16pt; FONT-WEIGHT: bold">CYTORI THERAPEUTICS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Exact name of registrant as specified in its charter)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Delaware</font></div>
</td>
<td valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: -63pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">001-34375</font></div>
</td>
<td valign="top" width="25%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 40.5pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">33-0827593</font></div>
</td>
</tr><tr>
<td valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(State or other jurisdiction of incorporation)</font></div>
</td>
<td valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: -54pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Commission File</font></div>

<div style="TEXT-INDENT: -54pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Number)</font></div>
</td>
<td valign="top" width="25%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 40.5pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(I.R.S. Employer Identification No.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3020 Callan Road, San Diego, California 92121</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Address of principal executive offices) (Zip Code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(858) 458-0900</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Registrant's telephone number, including area code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">n/a</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Former name or former address, if changed since last report)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<font style="FONT-STYLE: italic; DISPLAY: inline"> see</font>&#160;&#160;General Instruction A.2. below):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><a name="hangingindent"><!--EFPlaceholder--></a><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#9633;</font></div>
</td>
<td align="left" valign="top" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="&#61556;&#61537;&#61538;&#61490;"><!--EFPlaceholder--></a>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>



<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="3%">&#160;</td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#9633;</font></div>
</td>
<td align="left" valign="top" width="80%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> </font>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></font></div>
</div>
</td>
</tr></table>

<br>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="3%">&#160;</td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#9633;</font></div>
</td>
<td align="left" valign="top" width="85%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div>
</td>
</tr></table>
</div>
</div>

<div>&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="3%">&#160;</td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#9633;</font></div>
</td>
<td align="left" valign="top" width="85%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div>
</td>
</tr></table>

<br>
</div>

<div>&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 8.01 Other Events.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On August 5, 2014, Cytori Therapeutics, Inc.&#160;&#160;(&#8220;Cytori&#8221;) issued the attached press release providing an update on the status of the ATHENA trial.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 9.01 Financial Statements and Exhibits.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d) Exhibits.</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="69%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">Exhibit No.</font>&#160;&#160;&#160;&#160;&#160;</font></div>
</td>
<td align="left" valign="top" width="67%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">Description</font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td align="left" valign="top" width="67%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cytori Therapeutics, Inc. Press Release, dated August 5, 2014</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="41%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">CYTORI THERAPEUTICS, INC.</font></font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="41%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="47%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;Date:&#160; August 5, 2014</font></div>
</td>
<td align="left" valign="middle" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;By:&#160;&#160;</font></div>
</td>
<td align="left" valign="middle" width="51%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">/s/ Marc H. Hedrick</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="41%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Marc H. Hedrick</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="41%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;President, Chief Executive Officer</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXHIBIT INDEX</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="69%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Exhibit</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">No.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
<td valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="69%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Description</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
</tr><tr>
<td valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="middle" width="72%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="middle" width="72%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="69%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cytori Therapeutics, Inc. Press Release, dated August 5, 2014</font></div>
</td>
</tr><tr>
<td valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="middle" width="72%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cytori_pressrelease.htm
<DESCRIPTION>EXHIBIT 99.1 CYTORI PRESS RELEASE
<TEXT>
<html>
<head>
    <title>cytori_pressrelease.htm</title>
    <!--Licensed to: Cytori Therapeutics, Inc.-->
    <!--Document Created using EDGARizer 2020 5.4.6.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<img src="cytori_logo.jpg" alt="CYTORI LOGO"><br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CYTORI THERAPEUTICS CONTACT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Megan McCormick</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">+1.858.875.5279</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">mmccormick@cytori.com</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Cytori Provides Update on ATHENA Trial Status</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SAN DIEGO, August 5, 2014 &#8211; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Cytori Therapeutics</font> (NASDAQ: CYTX) has placed enrollment in the ATHENA and ATHENA II trials on clinical hold and therefore anticipates that it will not be possible to complete enrollment of the ATHENA I trial prior to the end of 2014 as previously anticipated. The decision to place the trials on hold was based on a safety review of reported cerebrovascular events. Symptoms occurred in three patients, of which two patients&#8217; symptoms fully resolved within a short period of time and the third patient has had substantial resolution of symptoms. Such events had not been previously reported in Cytori&#8217;s other cardiovascular trials and appear to be related in part to the medical co-morbidities in the treated population and the complex nature of the procedures involved in the trial.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The U.S. ATHENA and ATHENA II clinical trials are randomized, double-blind, placebo controlled studies designed to evaluate the safety and feasibility of adipose-derived regenerative cells (ADRCs&#8482;) in heart failure patients with ischemic heart disease who are already receiving maximal therapy with no options for revascularization. The procedure involves a fat harvest through small volume liposuction, cardiac catheterization, electromechanical mapping of the heart to determine where to inject ADRCs (or placebo), the actual ADRC (or placebo) injection and related data collection and monitoring activities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cytori has been working with the FDA, an independent Data Monitoring Committee (DMC), trial investigators and external expert consultants to fully understand any adverse events and to carefully define adjustments to the protocol intended to minimize risks to patients and to improve the benefit to risk profile of the study.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Adverse events are expected in trials in which participants suffer from advanced cardiac disease and protocol revisions during phase II safety and feasibility studies in compromised populations are common. Cytori is committed to refining the trial protocol as needed, to mitigate risks as much as possible. Updated information regarding enrollment projections will be communicated upon final protocol revisions and agreement amongst the investigators, the DMC and FDA<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font>as to the safety and feasibility of continuing the trial as amended.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Cytori</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions. Our scientific data suggest ADRCs improve blood flow, moderate the inflammatory response and rescue tissue at risk of dying. As a result, we believe these cells can be applied across multiple &#8220;ischemic&#8221; conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori&#8217;s proprietary technologies and products, including the Celution&#174; System product family. <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.cytori.com</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cautionary Statement Regarding Forward-Looking Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This communication includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, those regarding our ability to make the necessary and appropriate amendments to the Athena I &amp; II treatment protocols are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include the challenges inherent in mitigating procedural risks in compromised patient populations, our ability to satisfy the Data Monitoring Committee and the FDA as to the reasonable safety of continuing the trial, as well as other risks and uncertainties described under the "Risk Factors" section in Cytori's Securities and Exchange Commission Filings on Form 10-K and Form 10-Q. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this communication.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">###</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>cytori_logo.jpg
<DESCRIPTION>CYTORI LOGO
<TEXT>
begin 644 cytori_logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4`
M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@``
M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``@$!`@$!
M`@("`@("`@(#!0,#`P,#!@0$`P4'!@<'!P8'!P@)"PD("`H(!P<*#0H*"PP,
M#`P'"0X/#0P."PP,#/_;`$,!`@("`P,#!@,#!@P(!P@,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`$D`
MX`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/W\HHHH`:.E'0'->`?MA?\`!0CP7^Q]I;)J32:UKTBYATJU8+)T
MR#(YX1?P)]J_/3XV_P#!?GXH-INH?V;X-\*:5I5Q$8P)UNI;E5;C<LH=$#8/
M]ROHLLX5S'&P]K2A:/=M*_I?5GQF=<>9/EE?ZM7J7J=HINWK;1?-GUM^V1^W
M3XJO_%\GPY^#MJ]_KTC>3<:C$OF^43QMC[#_`'OR_AW?'G[4?_!';X\>-?A?
MKGCWQ)XXT[5-4TVQEU&XT^\O[B6X\J-"\BA]ICWX!(%?0O\`P0F^*OA_]H7P
M[XL\1-8_9?%^FSQI>H[B78LWF8DC;`X.QATX^85T_P#P5J_;VMO`?PVU'X9^
M"6_MKQIXH1K"<6K;UM(VX=#CJ2.&']W<.OW>R$:^#Q:P6'@E*-N9M7[-OTL)
MU,-F.">.J3<HRORI-K7:UN]]&>!?\&Z_[4/CSQ=XR\5?#OQ!K&IZYH>F6)O;
M-;V=[A],=71617;)5#O^[TS7ZTK7Q-_P1E_X)_WO['OP8NM<\30^7XR\8*LM
MQ$X(>SA)W;#GD.QP6'^PO0[J^V`,CKWKQ<ZK4ZF+E*E:WEU?5GN9#1JTL'&%
M:]_/HNB'44#I17EGL!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`#=V*\U_:K^-"_`?X,:IKBX-YM^SV8(SF9E8@_@%)_"O2CTKP?\`X*#>
M`KGQW\#0ENI?[#?13R#_`&!G)_I^-=F6TZ<\5"%7X6U<\W-JE6&$J2H_%9V]
M3P+]AW]CJQ^.NL7GQ*^(4)URXGN&-O;W3%T9R=Q9L_>`SGW_`.^MU[_@N/X\
M\$_#S]A;4/!]]#ID.H>(KBVCTBT5$5H#%.DDDJH,;0$#)D?\]/[NZLOXZ?\`
M!1O0?^":W[*5I%=6)U;Q9J#.NC:?RL4I*@!Y,<[!CHOWO]GYBOS!^R3_`,$Y
M_BK_`,%5OB3'\9OC]JVHZ;X6O'$MCIZCRY[Z)6XCB3I##_M8^G?;]I!R>-_M
M#&SY:--^ZN]MDDOQ/SG%4(++WE674^>O55I2MMS+5MOK;;730Z'_`((P?!#Q
M1X6^!'B77=/U#^R&\?7$6F6#2-Y7F10>9NES_=+/M'^ZU?>?[./_``3W\(_!
M37V\3:E&OB#Q<[>9]MNEWK;-G.8P>X_O5YC^UG;:;\`M>\*>&?#-O!I>FVZV
M\5I90?+'`J%%`_*OL3P_=R7NA6,TW^MF@C=_]XJ":\7/LTJXFH\3'W54Z+>R
MLE=^A]7PSDM+`X6&#E[TJ:W\VVVTO5FE10.*,YKYD^M"BC-&:`"BC-!-`#0#
MGTHQC_\`50HKX=_X*H?\%'O'G[#_`(]\*Z3X3TOPG?6^N6$MW.^K6UQ,ZLC[
M0$\J:,8QZBM\+AJE>HJ5):LY<9C*>&INK5V7;4^XR*0+Q7F/['_QBU3X_P#[
M-'@_QEK,%C;ZIX@T];NYBLT=($<EAA`[,0O'=C7IY-95*;A)PENM/N-J-2-2
M"G'9BT445)H%%&:*`"BC-%`!1110`4444`%%%%`'(_%KXO>'?@?X)NO$7BC4
MK?2M)LUR\TK@;B>BJ.K,>P%?)7A+]MGQ7^W1XYFT?X?Z+<V/A*"7;/>SQ?-.
M@/WF)X4>W_H7RU\>?M(_&3Q%_P`%0OV_=,\!Z7J3Q>%8M3?3],@C),*6Z$F:
M[*Y&YV1&D_W=J]J_6;X5_"CPI^R_\*H='T>"UT?1])AW2S/C<^!S)(W&YC_]
M85]IB\KH9/AZ?MX\V(J*Z72*Z7ZM_J?F&5\08KB'&U?JLN3"4G9RZS?D]DDM
M?1GX/_\`!0GXR6]S_P`%7-/TGX@221^%O".J0Z;<A5+K!#&Y3S4&,XX\SZLU
M?LMXK_X**_!#X4^`K>;2?&WA?6;>&W1+*PT2\BNF*!`$0",D(`,=>@[5\#_M
M$?L"^$?^"K'[<.H:EIUSJF@,IQ>:G9*KI+%&>'DC88W;>.".=O\`>KZ5_9U_
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M6^.E_P"#@WXE'6C(W@OP.VF$Y\A?M0G^]_SU\W'W?]C_`.)KPO\`8N^"-U_P
M4+_;:6U\5WUS/#JTUQK_`(@N(VVR2Q*VYT0]MSND?^P&_P!FOUZ_X=S?`T^#
MO[#_`.%6^"Q9^7Y7F?8%^V8QC_CZ_P!?N_VM^:]^O2R_`<M*M!SFU=OM^)\W
MAZV8YBY5J$U""=DN_P"!PO["_P#P5+\$_MIWG]B_99O"?C2.,R?V3=3B9+M%
M&6:WEPOF8')4JK]]I4;JX;_@HQ_P4^\:?L-?&>QT*U\&:+K&B:OIR7]G>W%S
M+&[D,4EC(7C<I&?HZUZ/^R+_`,$N_AS^R'X]U?Q-HZ76LZQ>3N-.GU(B1M&M
MV_Y8Q?[?W@93\Y7`_O;N$_X+A?L]?\+;_9)7Q19P^9JWP_NA?A@N6:TEQ'<+
M^'[J0_\`7*O/H_498Z,8)\DM->C?8]&O]?CE\I3:52.MUV7_``#Z7_9J^-5G
M^T9\!/"GCBQC2&/Q%I\=U)"K;Q;3?=EBSQGRY%=,_P"S7F7_``4>_;@_X88^
M#^FZY9Z99ZQK6L:DEA9V=Q*8D9`C/+(2O.U54#_>D6OG[_@W^^/?_"3_``;\
M4?#NZF9KKPO?#4K%2W_+K<<.BC^ZDR,3_P!=Q7SO_P`%S?CC)\5?VN;/P?92
M27%GX%L8[3R4R^Z]N-LLN,=]A@7ZK6V&RI/,98>:]V-V_3I^AEB<XDLLCB(/
MWY))>O4^_O\`@FS^V-XH_;:^&>N>*M=\-Z;X=T^SU`6&GBUEDD-RRINE8[_X
M1O0#'^U7Y=_\%1/VMM2_:C_:#NK2_P!'L]+7P'=7VAV[6\CNUTB7+C>^[[K?
M)VK]@_V+?@)'^S3^S#X+\'&-4O-,T]'U#;SNO)/WL[9[_O68#VQ7Y[?\'#B[
M?C)\/??1K@_^1JZ,FJT?[2:IQT=^7?1+_,YL\HU_[,BZD]5;FT6K;_1G6?\`
M!(O_`(*0:UXT\4^!?@C)X;TN+2[#3;B)=3CN)#<$0Q22@E3QR1BOTPD98P69
M@JKR2>F*\+_X)EC_`(P+^%_R_P#,&CY_X$U8O_!6?XD7OPN_8-\=7NFS/;WF
MHPP:4DBG#*EQ.D<N/K$SBO,QD8U\=[.G'EO*V]];V;_X!ZN!E/#8'VM67-:-
M]K:6V_X)X#^UA_P7@T7X;>+;S0/AMH5MXMET^0Q3ZQ>7!33W<<'R43YI4_V]
MR+Z;A\U>8_#3_@X3\76VMQ?\)AX#\.WVFNV)#H\\]K-$I/WAYK2!B/[O&?5:
MY'_@BU^Q%X5_:;\4^*O$_C738]:TGPO]GM[+3YMWV:YN)=[,\@!&\(J+\AX/
MF\U]=?\`!1#_`()K?#'Q?^S1XJUOPSX/T'PGXD\+Z9/JMG<:/91V:S>0C2/#
M)'$%1]Z*5!(R#MYXKV:T,LP]98.<&WHG+S?S/#HU,UQ%%XR$TEJU'R7R_4^E
M/V?OV@_"_P"T[\,;#Q=X1U%;_2;[*L#\LUI*H&^&5,G9(F1D?0C*L"8?VK?C
M/=?L]?L[>+/&ME8PZC=>'+!KN.VF<I',00-I(Y[U^;/_``;Z?$Z\T[X[>,O!
M[7#?V;JNB?VJL3-QY]O/'%N`]2DYS_N?[-?>?_!3+_DPCXH_]@9__0EKQ\5E
M\:&.6'>L6U]S:/:P>93Q&7NNM))/[T?(7P\_X."$E\)>(KSQ3X+MX]6M5@71
MK#3KF3;?._F>8997!$:+MCZ!F^;I_=X73?\`@X2^(:>)UEN_`O@ZXT<M_P`>
ML$MS%<XST\XNR;O^V=>>_P#!'#]C_P`-_M5_'36KKQ?9#5-`\(V*71L&<K%=
MW$DFV(28()1520X_B^7/&Y6_4:?_`()_?!D>--!U^W^&_A72]4\,W"W5A+IU
MDMFJR#[K21Q;4E(;##>&PRJ:]?'?V;A*LJ+I\SMWT6FG7[SQ<O6:8RC&K&JH
MJ_S>NO0]$^%?C2\^(7PZT77;S1-2\-W6J64=U+I=_L^T6)89\M]I(S^OJ%.5
MKX;_`&6/^"R7B?\`:`_:RT'X=WG@O0]/LM6OKBT>\@NI7EC$<<CA@#QSY=?H
M2X_=D>@K\+/^":W_`"D]\&_]AB^_])[FO.RK"TJU*M.4?A5UOIN>IG&+K4*M
M"$)6YG9[:['[K`Y%%`X%%>&?1!1110!^$?C']D#X\?L%_M&+KWAWPQXBO)=!
MO7GTS6]+TU[ZTNHL,-S[`ZIN0L&CDVM7T)X8M_VNOV_+J'3?$5KJ'A/PN)1Y
M\EU8'2H64<$[&`DEY^M?JHT88<JI^M"K@_*%7Z5]UB..JM:*E4H0=6*LIM7:
M]%WOJ?E.#\*Z&%FZ='%5(T&[N"=D_)OJK:/2[[GE?[+/[+6A_LN>!DTO3&DO
M+R<*UY>RC#SN!UQ_"/:O50/E]Z4+D4-P:^*Q&(J5JCJU7>3W9^FX3"4L-2C0
MH+EC%62'$9%<#^TSX/G^(/[.?CWP_:JTEQKGAW4+")4^\SRVTD8`X/.6KOL\
M4TG*X-9PERR4NVIK4IJ<7'N?BC_P0Z^)&G>`/VY(;/4)5A_X2K1+K2+9GX4S
M&2&X5<^I^SX'OQ7[79S7Y"_\%(?^"4GC3X6?%?4?'GPMTJ^USPWJEX=0^Q:4
MKOJ.B7#-YC[(T&]H]_*-'\R=#MVJS>.M_P`%'?VF'TMO"/\`PFWBD2M'Y)@_
MLV)=2QG;Q-Y7V@-N_BW[J^OQV`CF4HXG#S6J2:>ZL?%X#,IY9&6%Q%-Z-V:Z
MW/W,TW7++5Y[A;.ZM[I[.8V]QY4@D\F10"4?!X<!AP>:A\9^$[#Q_P"$M4T/
M5(%N=-UBSELKJ(])894*.OXJ37YS_P#!&W]DOXT_#GXD7WC;Q1=:QX6\)ZM%
M(UWH^I9:Y\03./DE>)_FCVL=WFMAV^[]UFK]+LY%?-8S#QP]9PIR4K=5W/J,
M#B98JCSU(.-^C['X<_LG?$:3_@FA_P`%$M2L?$LUQ#I.CW%]H.K.L9W7-LW,
M,H`_A+I;R_[M/_X)U_#Z_P#VV?\`@HS9Z_K<9N([?4KCQAK&<E`4F\R-.>QN
M'B7']RO4?^"_WP2L_!OQW\+^-K5H8W\9:?);7L0(#M/9^6JS$9RV8YHD_P"V
M0KW3_@@3^S\W@OX":]\0+R$K>>,[W[+9,5_Y<[8E=P_WIC*#_P!<EKZ_$8N"
MP+QJ^.<5'YW:_P`_N/B\/@JCQZP3^"$G*WE9/_+[V??P'/TK\G_^#AW_`)+)
M\//^P-<?^CJ_6+I7P'_P6V_8S\4_M!>$/#'B_P`&Z7=:YJ'A47%MJ&G6L?F7
M<]O(49)(D'+^6Z'*+EOWG`X-?-Y'6A3QD95'9:K[T?4<049U<%*%-7>C^YH^
MA/\`@F7S^P5\+O\`L"I_Z$U>?_\`!;'0GUC_`()_>)9T5V_LV_L+IMOH;I(N
M?^_E?+/_``2)^.?QNT[X[^$_AKKTGB*S^'=E:WRBQO-#2)(2L4DBK]H:(2KB
M3H-_M7Z8?&3X5Z7\</A=KWA'6XWDTOQ!8R65QL.UT#C`=3_"ZG#+[@5IBJ;P
MF/52337-S:=F_P`R,'+ZYESIQ33Y>77NE;[CX!_X-X/%]E)X4^)7A\R*FH1W
MEGJ`C+<RQ,DD98#V9.?]Y:^U?VUO%ECX(_9%^)6I:A.EO:P^&[^,%FV[GD@>
M.-!_M-(Z*/=A7X__`!@_9*^-_P#P3=^,,NJZ"GB"&UM6=-/\3:+!(]M=0L>%
MEV[@A/\`%%+WZ;E^:L+Q?\?/VA/^"@7V/P[>7GBKQW"LP>.PT[3$BMO,7H\B
MV\:1_+G[\G2O8Q64QQ6*^MPJ+D=FW?:UO\NIXF%S>>%POU*=-\Z325M[GLG_
M``0&T2:__;+UN\4,L-CX6NBQV\9>YM5"_C\Q_P"`U^C'_!308_8*^*/_`&!G
M_P#0EK@_^"6/_!/^;]BOX7W]YX@:&;QQXK\M]2$3!X].C0$QVR,,AF!=B[CA
MC@?,$5F]`_X*/Z5=:U^PU\2K.SMY[RZN-'=8H((S))*=Z\!1DFO*QV*A7S*-
M2#NDXJ_>S1ZV7X.=#*Y0FK2:;MVNCXF_X-U_^1S^*G_7IIW_`*'<5^IG2OS&
M_P"#?KP-K?A'Q?\`$]M6T?5M+6XM=.$9N[.2W$I#W&<;@,XS7Z<9R166?R3Q
MLFO+\D;\.1<<#!/S_,'Y5OI7X5_\$U?^4GW@W_L,WW_I/<U^ZC\(:_$C_@G3
M\+O$VB_\%*?!U]>>'=>L[&/5[UFN)M/E2-0;>Y`)<J%[UU9')*AB$W]G_,Y.
M((MU\.TOM?JC]N:***^=/J`HHHH`****`"BBB@`HHHH`,9I-B_W1^5+10%D-
MVUY[^TI^T1X?_97^$M_XT\31ZA)H^FR11S+91"6;,D@1,*64?>8=Z]"DKY)_
MX+6?\H^/%O\`U^Z=_P"EL5=&"HQJUX4I;2:3./'UI4</*I#=*Y^</[?'[5-U
M_P`%(?VJ-#B\)Z9J4>FQK%HF@65SCS[F623F5D4LJF1W4=3\BK7[1_`KX3V7
MP+^#?AGP?I^UK7P[IT-BKA=OG,B`/(1ZNVYC[M7XJ_\`!(K_`)2&>`?^NMU_
MZ0M7[MQ=*]_B2*H>SPM/X4K_`-?UU/G>%FZZJ8RIK*3^[T_KH+GI28YJO#_K
M/PI'^ZOT'\C7RW=GUE^A:"X-*1FJDO\`J&^H_E3_`.-/I_A1S:LKH6",T@11
M_"/RJ$=OK42?Q?\``J(ZL'%7+1^8TI.[BH/XV_WA_2F?\MW^J_SH4M;>0F];
M%H+Z4N=U4Y/]9^?\Q3A_K!_NK_.J&6!_=HVJ#52?_7O_`+J_S-/?JWX_TI)@
LT6J"N:JO_K)/]W^M*_\`K%^M)LGF+"?=I%&#41^\OX_SJ+_EK_P(U11__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
